Cargando…

Prognostic value of tumor mutations in radically treated locally advanced non-small cell lung cancer patients

INTRODUCTION: Chemo-radiation is standard treatment in locally advanced non-small cell lung cancers (NSCLC). The prognostic value of mutations has been poorly explored in this population. RESULTS: Clinical data were collected from 190 patients and mutational profiles were obtained in 78 of them; 58...

Descripción completa

Detalles Bibliográficos
Autores principales:	Boros, Angela, Lacroix, Ludovic, Lacas, Benjamin, Adam, Julien, Pignon, Jean-Pierre, Caramella, Caroline, Planchard, David, de Montpreville, Vincent, Deutsch, Eric, Levy, Antonin, Besse, Benjamin, Pechoux, Cécile Le
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5421921/ https://www.ncbi.nlm.nih.gov/pubmed/28445990 http://dx.doi.org/10.18632/oncotarget.15966

Ejemplares similares

Neutrophilia as prognostic biomarker in locally advanced stage III lung cancer
por: Schernberg, Antoine, et al.
Publicado: (2018)

A phase II open-label multicenter study of gefitinib in combination with irradiation followed by chemotherapy in patients with inoperable stage III non-small cell lung cancer
por: Levy, Antonin, et al.
Publicado: (2016)

Immune-related arthritis following pelvic radiation therapy in a patient with lung cancer receiving long-term immune checkpoint blocker treatment: Case report
por: Aldea, Mihaela, et al.
Publicado: (2022)

Stereotactic body radiotherapy for extra-cranial oligoprogressive or oligorecurrent small-cell lung cancer()
por: Levy, Antonin, et al.
Publicado: (2023)

Real-World Utility of an Amplicon-Based Next-Generation Sequencing Liquid Biopsy for Broad Molecular Profiling in Patients With Advanced Non–Small-Cell Lung Cancer
por: Remon, Jordi, et al.
Publicado: (2019)

(18)F-FDG PET and DCE kinetic modeling and their correlations in primary NSCLC: first voxel-wise correlative analysis of human simultaneous [18F]FDG PET-MRI data
por: Besson, Florent L., et al.
Publicado: (2020)

Chronic Plasma Exposure to Kinase Inhibitors in Patients with Oncogene-Addicted Non-Small Cell Lung Cancer
por: Geraud, Arthur, et al.
Publicado: (2020)

Durvalumab for stage III non-small-cell lung cancer patients: clinical evidence and real-world experience
por: Botticella, Angela, et al.
Publicado: (2019)

Impact of missing individual patient data on 18 meta-analyses of randomised trials in oncology: Gustave Roussy experience
por: Fayard, Florence, et al.
Publicado: (2018)

Integrin-α(V)-mediated activation of TGF-β regulates anti-tumour CD8 T cell immunity and response to PD-1 blockade
por: Malenica, Ines, et al.
Publicado: (2021)

Thoracic radiotherapy in small cell lung cancer—a narrative review
por: Levy, Antonin, et al.
Publicado: (2021)

Meningeal “Lazarus Response” to Lorlatinib in a ROS1-Positive NSCLC Patient Progressing to Entrectinib
por: Facchinetti, Francesco, et al.
Publicado: (2021)

Brain Radiation Necrosis: Current Management With a Focus on Non-small Cell Lung Cancer Patients
por: Loganadane, Gokoulakrichenane, et al.
Publicado: (2018)

Prognostic value of histogram analysis in advanced non-small cell lung cancer: a radiomic study
por: Virginia, Bluthgen Maria, et al.
Publicado: (2017)

Association of the prognostic model iSEND with PD-1/L1 monotherapy outcome in non-small-cell lung cancer
por: Park, Wungki, et al.
Publicado: (2019)

Role of adjuvant radiotherapy in completely resected non-small-cell lung cancer
por: Péchoux, Cecile Le, et al.
Publicado: (2013)

Tumour motion management in lung cancer: a narrative review
por: Botticella, Angela, et al.
Publicado: (2021)

Immune biomarkers in thymic epithelial tumors: expression patterns, prognostic value and comparison of diagnostic tests for PD-L1
por: Rouquette, Isabelle, et al.
Publicado: (2019)

Complete Remission After Immunotherapy-Induced Abdominal Tuberculosis in a Patient With Advanced NSCLC Treated With Pembrolizumab: A Case Report
por: Riudavets, Mariona, et al.
Publicado: (2022)

EGFR C797S, EGFR T790M and EGFR sensitizing mutations in non-small cell lung cancer revealed by six-color crystal digital PCR
por: Madic, Jordan, et al.
Publicado: (2018)

Correction: EGFR C797S, EGFR T790M and EGFR sensitizing mutations in non-small cell lung cancer revealed by six-color crystal digital PCR
por: Madic, Jordan, et al.
Publicado: (2019)

AB008. Activated pathways of Thymic Epithelial Tumors: a RYTHMIC study
por: Benitez, Jose Carlos, et al.
Publicado: (2022)

Outcomes in oncogenic-addicted advanced NSCLC patients with actionable mutations identified by liquid biopsy genomic profiling using a tagged amplicon-based NGS assay
por: Remon, Jordi, et al.
Publicado: (2020)

Crystal digital droplet PCR for detection and quantification of circulating EGFR sensitizing and resistance mutations in advanced non-small cell lung cancer
por: Jovelet, Cécile, et al.
Publicado: (2017)

Prospective evaluation of intensity-modulated radiotherapy toxicity in extremity soft tissue sarcomas patients: A role for irradiated healthy soft tissue volume?
por: Bourdais, Rémi, et al.
Publicado: (2021)

Impact of Intercurrent Introduction of Steroids on Clinical Outcomes in Advanced Non-Small-Cell Lung Cancer (NSCLC) Patients under Immune-Checkpoint Inhibitors (ICI)
por: De Giglio, Andrea, et al.
Publicado: (2020)

CD103(+)CD8(+) T(RM) Cells Accumulate in Tumors of Anti-PD-1-Responder Lung Cancer Patients and Are Tumor-Reactive Lymphocytes Enriched with Tc17
por: Corgnac, Stéphanie, et al.
Publicado: (2020)

Comment on Hopkins et al. Value of the Lung Immune Prognostic Index in Patients with Non-Small Cell Lung Cancer Initiating First-Line Atezolizumab Combination Therapy: Subgroup Analysis of the IMPOWER150 Trial. Cancers 2021, 13, 1176
por: Auclin, Edouard, et al.
Publicado: (2021)

Unexpected Cardiotoxicity in Patients With HER2-Mutant NSCLC Treated With Trastuzumab Deruxtecan: A Case Report
por: Riudavets, Mariona, et al.
Publicado: (2022)

Oncogenic Fusions May Be Frequently Present at Resistance of EGFR Tyrosine Kinase Inhibitors in Patients With NSCLC: A Brief Report
por: Enrico, Diego, et al.
Publicado: (2020)

Prognostic value of KRAS subtype in patients with PDAC undergoing radical resection
por: Dai, Manxiong, et al.
Publicado: (2022)

Prognostic Value of the Modified Glasgow Prognostic Score in Patients Undergoing Radical Surgery for Hepatocellular Carcinoma
por: Ni, Xiao-Chun, et al.
Publicado: (2015)

Osteopontin and thrombospondin-1 play opposite roles in promoting tumor aggressiveness of primary resected non-small cell lung cancer
por: Rouanne, Mathieu, et al.
Publicado: (2016)

Prognostic Value of an Immunohistochemical Signature in Patients With Bladder Cancer Undergoing Radical Cystectomy
por: Wu, Jie, et al.
Publicado: (2021)

Molecular guided therapy for advanced pancreatic cancer patients with PI3K activated mutation: vision or illusion?
por: Gazzah, Anas, et al.
Publicado: (2013)

Prognostic value of clinicopathological parameters in head and neck squamous cell carcinoma: a prospective analysis.
por: Janot, F., et al.
Publicado: (1996)

Prostate Volume has Prognostic Value Only in Pathologic T2 Radical Prostatectomy Specimens
por: Cho, In-Chang, et al.
Publicado: (2011)

The prognostic value of lymphovascular invasion in radical prostatectomy: a systematic review and meta-analysis
por: Huang, Yi, et al.
Publicado: (2016)

Prognostic value of inflammation-based scores in patients receiving radical resection for colorectal cancer
por: Wang, Fang, et al.
Publicado: (2018)

Prognostic value of vascular mimicry in patients with urothelial carcinoma of the bladder after radical cystectomy
por: Zhou, Lin, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_gnkde13tpo9m20522mg7lokmur